Intesa Sanpaolo completes latest round of share buybacks for cancellation

Gian Maria Gros-Pietro Chairman of the Board of Directors of Intesa Sanpaolo Wikipedia
Gian Maria Gros-Pietro Chairman of the Board of Directors of Intesa Sanpaolo - Wikipedia
0Comments

Intesa Sanpaolo announced that it has completed a series of share buyback transactions between September 22 and September 26, 2025. The bank stated that these purchases are part of its previously disclosed programme to buy back shares for cancellation, which was initially communicated to the market on May 26, 2025, and began on June 2, 2025.

According to Intesa Sanpaolo, the execution of these transactions was carried out by Morgan Stanley Europe SE. The intermediary acted independently and without any involvement from the Intesa Sanpaolo Group. The purchases took place on the regulated market Euronext Milan managed by Borsa Italiana.

During this period, Intesa Sanpaolo acquired a total of 22,246,915 shares. This amount represents approximately 0.12% of the bank’s share capital. The average purchase price was reported as 5.4254 euro per share, with an overall expenditure of about 120.7 million euro.

The bank noted that these actions are in line with applicable regulations and form part of its ongoing efforts related to share capital management.



Related

Paul Hudson Chief Executive Officer Sanofi SA

Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

Volvo announces updated share and vote count after series conversion

The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

Paul Hudson Chief Executive Officer Sanofi SA

Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

Trending

The Weekly Newsletter

Sign-up for the Weekly Newsletter from EU Business Daily.